The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.
The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.
Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.
The co-founder of IRB Barcelona and president of its External Advisory Board receives today, together with Manel Esteller and Josep Baselga, the Catalonia International Award presented by the Government of Catalonia.
Scientists from the US, Canada and Spain, among them Joan Guinovart from IRB Barcelona, are poised to perform joint research with the aim to find a treatment for Lafora disease, the most severe type of epilepsy in humans.
The National Health Institutes has awarded the consortium $8.5 over five years.
The US organisation Chelsea’s Hope, a charity formed by families affected by this disease, has promoted this international collaboration.
Miquel A. Pericàs, director of the Institute of Chemical Research of Catalonia (ICIQ), has taken over as general director of the Barcelona Institute of Science and Technology (BIST). He succeeds Montserrat Vendrell, the first director of the organization, who is moving on to take up an entrepreneurial post in the private sector.
The Meet Our Scientists video series introduces Jens Lüders, who studies microtubules—mini-filaments involved in multiple cell processes. The alteration of these structures is associated with diseases such as cancer and Alzheimer’s and with developmental defects.
In the video “Curiosity as a fuel”, Lüders recalls that transcendental discoveries arise from basic research and that such science is driven exclusively by curiosity, without specifically pursuing its applicability or transfer.
For the fourth consecutive year, the CosmoCaixa will bring together researchers from all over the world to participate in a B·Debate, an initiative of Biocat and the Obra Social “la Caixa”. To be held on 13 and 14 October, this B.Debate organized by IRB Barcelona scientists, will address the latest advances in cancer
The morphology of the tumour cell changes when the cell migrates from one site to another, thereby allowing the cell to evade regulation and thus facilitating metastasis
Cancer relapses after chemotherapy are caused by tumour stem cells that survive the treatment
From today and until Wednesday, 150 scientists from around the world will debate plasticity and cell migration in the new gathering in the Barcelona Biomed Conference Series, organised by IRB Barcelona and the BBVA Foundation.
The 28th conference in this series brings together biologists devoted to the study of development in animal models, specialists in cancer, and paediatricians.
The Bilbao Exhibition Center (BEC) in Barakaldo (Vizcaya) is the venue of BioSpain 2016, the eighth of these biennial biotech gatherings, the most important event in this sector in Europe and permanently held in Spain, and fifth-ranked event worldwide for the number of partnering meetings held.
Today the Asociación Española Contra el Cáncer (Spanish Association against Cancer) presents its 2016 Research Awards in Barcelona.
Two research projects on colon cancer will receive funding over five years.
To date, IRB Barcelona has received AECC funding for eight studies.
The University has awarded this honour in recognition of his “outstanding career in biochemistry and his contributions to research, in particular, in relation to alterations in diabetes and to Lafora disease